By using the CRISPR-interference screening method in transgenic mouse models of primary liver cancer, KIF23 was determined as the key downstream target of TAZ, and reduced KIF23 expression markedly inhibited tumor initiation of HCC models, indicating the attractive significance to exploit pertinent inhibitors or relevant chemo-modifications targeting KIF23 in HCC treatment [87]. The gene discussed is KIF23; the disease is liver cancer.